Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures

• Published in: Alimentary pharmacology & therapeutics 1999-08, Vol.13 (8), p.1041-1045
• Main Authors: BARBEZAT, G. O, SCHLUP, M, LUBCKE, R
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents - therapeutic use; Biological and medical sciences; Digestive system; Dilatation; Enzyme Inhibitors - therapeutic use; Esophageal Stenosis - drug therapy; Esophageal Stenosis - etiology; Esophageal Stenosis - surgery; Esophagoscopy; Female; Gastroesophageal Reflux - complications; Histamine H2 Antagonists - therapeutic use; Humans; Male; Medical sciences; Middle Aged; Omeprazole - therapeutic use; Pharmacology. Drug treatments; Proton Pump Inhibitors; Retrospective Studies
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1046/j.1365-2036.1999.00582.x

Background : Better control of gastric acid secretion with omeprazole appeared to decrease the need for dilatation of oesophageal strictures complicating gastro‐oesophageal reflux disease in our hospital‐based endoscopy service. Aim : To investigate whether the perceived decrease in the need for oesophageal dilatation could be documented from endoscopy records, and, if confirmed, whether this could be related to the treatment used. Patients and methods : Retrospective study of the records of 69 patients who had peptic oesophageal strictures dilated, followed by treatment with acid inhibition for at least 6 months. Mean duration of follow‐up was 3.9 years during treatment with H2‐receptor antagonists and 2.1 years while on omeprazole (258 and 78 patient‐years, respectively). Re‐dilatation rates were compared between those treated with H2‐receptor antagonists or omeprazole. Results : There has been a significant decrease in dilatations performed for gastro‐oesophageal reflux induced strictures (P